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which temozolomide, nimustine, doxorubicin, and teniposide
were most common. 53% of these patients received subsequent
chemotherapy regimens.forty-four percent (16/36) underwent
surgery initially for their recurrence, with 81% (13/16) of these
patients receiving subsequent chemotherapy. Other drugs used in
treatment of recurrent disease included doxorubicin and lomus-
tine. CONCLUSION: Consistent with published guidelines,
GBM patients in Germany with better functional status undergo
active therapy. Patients initially undergo surgery, followed by
radiotherapy. Chemotherapy is often used with or immediately
following radiotherapy or at disease recurrence.
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OBJECTIVES: This oncology-speciﬁc organization integrated
into its electronic medical record (EMR) system a series of clini-
cal pathways (CPs) based on national guidelines. The objective
was to to evaluate adherence to pathways and develop a pro-
cess for communication to practices regarding performance.
METHODS: The CPs are based on clinical and economic litera-
ture and are physician-led. Adherence is measured using a com-
bination of patient disease, stage of disease, and line of therapy.
A combination of methods has been used in the reporting
process, including web-based reports; involvement of staff phar-
macists to promote and monitor clinical pathway adherence at
the local level; multiple teleconferences among pharmacists and
physicians to discuss cases, share successes, failures, and ideas;
and inclusion of network pathway reports for all attendees at the
organization’s biannual national P&T meetings. RESULTS:
Eighteen practices have EMR pathway reporting capabilities,
with new practices being added every month. Currently clinical
pathways for 7 cancer types have been implemented into the
EMR system. Pharmacists have increased their role in promoting
pathway adherence. One of the greater challenges has not been to
improve pathway adherence per se, but to increase completion
of key elements of evaluation, including disease stage and line of
therapy. CONCLUSION: Early evaluation shows monitoring of
pathways can be conducted with use of an EMR. Regular feed-
back on missing data has encouraged providers to update clinical
data entry. The complexity and dynamic nature of oncology
treatment requires frequent evaluation of clinical pathways to
ensure they are current and are based on both clinical and
economic evidence.
CANCER—Methods and Concepts
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OBJECTIVES: Conventional cost-effectiveness analysis are
usually supported by clinical data collected in phase III RCTs
(Drummond, 2005) and it is typically based on time-to-event
data. However, ignoring mean quality-adjusted survival for mul-
tiple transitions may introduce some estimates bias. Multi-state
models appeared to eliminate some limitations of Q-TWiST
models such as the necessity for progressive states (Billingham,
1999), but the applicability of these models in heath economics is
still unclear. The aim of this analysis is to compare the results of
two modeling alternatives: conventional cost-effectiveness analy-
sis and multi-state cost-effectiveness analysis taking capecitabine
versus docetaxel in mBC in Brazil as a study case. METHODS:
Conventional and multi-state survival analysis techniques were
applied on O’Shaugnessy (2001) data to perform both cost-
effectiveness analysis. For the conventional survival analysis, a
Cox and parametric approach were used, and the best ﬁt was
chosen analyzing Cox-Snell and deviance residuals, as well as
AIC and BIC criteria. For multi-state survival analysis, the model
estimation was based on Gardiner (2006), and assumed as a
three-stage non-homogeneous Markov process. For costs, the
resource use was obtained from O’Shaugnessy trial and unit costs
were derived from published lists such as CBHPM 2004, Simpro
magazine and PROAHSA report. RESULTS: In conventional
analysis the incremental cost-effectiveness ratio (ICER) was
R$26,208 per QALY assuming log-logistic distributions which
was the best ﬁtted one, meanwhile in multi-state analysis, the
incremental cost-effectiveness ratio was R$19,320 per QALY
using weilbull distributions (Klein, 1994). PSA was performed
using Monte-Carlo simulations that supported the robustness
of the ﬁndings. CONCLUSION: Despite multi-state analysis
demands more sophisticated statistical background, there is an
evident superiority in multi-state estimates precision and accu-
racy when performing cost-effectiveness analysis. Regarding to
capecitabine, it was observed that in both models its addition in
this setting could be considered as a cost-effective alternative
under the private payer perspective in Brazil.
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OBJECTIVES: To investigate the impact of chronic lymphocytic
leukaemia (CLL) on health-related quality of life (HRQL) and
the gain in terms of descriptive richness associated with using an
EQ-5D with additional levels (EQ-5D-5L) in the CLL patient
population. METHODS: The EQ-5D-5L employed in this study
incorporates 5 levels of assessment but without additional label-
ling (Levels 2 and 4 are unlabeled). Our study involves a cohort
of patients with CLL from 19 participating Dutch centres.
Health-related quality of life (HRQL) is assessed at 6 monthly
intervals. The following analysis is based on the initial HRQL
assessment, which captured patients at various phases in their
disease course. RESULTS: In March 2006, 134 patients had
completed at least one EQ-5D-5L questionnaire of whom 63%
were male of median age 66 years. Median age for females was
higher at 70 years. Most patients (72%) were in remission at the
time of the ﬁrst HRQL assessment. Twenty-six percent selected at
least one alternative level on the EQ-5D-5L. The dimensions
where patients reported most problems were Pain/Discomfort
(level 1: 57%, level 2: 8%, level 3: 32%, level 4: 1%) and Usual
Activities (level 1: 62%, level 2: 7%, level 3: 28%, level 4: 2%,
level 5: 1%), followed by the Mobility dimension (level 1: 69%,
level 2: 8%, level 3: 22%). Few patients reported problems in
terms of Self-care (5%). The mean VAS score was 75.08
(SD = 14.3). Utility scores were 0.88 (SD = 0.15) for the EQ-5D-
5L, slightly higher than for the 3-level categorization at 0.84
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(SD = 0.15). CONCLUSION: Results obtained thus far suggest
that the HRQL of CLL patients in remission is high. Patients
utilize the additional categories provided with a 5-level instru-
ment. However, in this case the labelled levels still attracted the
greatest percentage of answers, which may be a function of the
design of the questionnaire.
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OBJECTIVES: Progression-free survival (PFS) has not been vali-
dated as a surrogate endpoint for overall survival (OS) for
anthracycline-based (A) or taxane-based (T) chemotherapy in
metastatic breast cancer (MBC). Using a meta-analytic trial-level
approach, we evaluated the relationship between PFS and OS.
METHODS: A literature review identiﬁed all randomized, con-
trolled A and T trials for MBC. Progression-based endpoints
were classiﬁed by prospective deﬁnitions. Treatment effects were
derived as hazard ratios (HR) for PFS (HRPFS) and OS (HROS)
from trial data (constant rate assumption). The kappa statistic
assessed overall agreement. HROS was predicted from trial HRPFS
using ﬁxed effects models that were internally validated. Sensi-
tivity and subgroup analyses were performed for the constant
rate assumption, PFS deﬁnition, year of last patient recruitment,
and line of treatment. RESULTS: Inclusion criteria were met by
15 A and 16 T trials, allowing 17 A (n = 4155) and 17 T
(n = 5509) comparisons. The direction of HROS and HRPFS
agreed in 25% (A) to 50% (T) (negative) and in 62.5% (A) to
50% (T) (positive) (kappa = 0.71, p = 0.0029 (A); kappa = 0.75,
p = 0.0028 (T)). HRPFS was a signiﬁcant predictor of HROS for A
(p = 0.0019) and T (p = 0.012) in the ﬁxed effects models, with
explained variance (R2) of 0.35 (T) and 0.49 (A). Cross valida-
tion showed that 97% of the 95% prediction intervals crossed
the equivalence line. The direction of predicted HROS agreed with
observed HROS in 82% (A) and 76% (T). Results were robust in
sensitivity and subgroup analyses. CONCLUSION: This analysis
suggests the treatment effect on PFS is signiﬁcantly associated
with the treatment effect on OS. However, prediction of OS
based on PFS is surrounded with uncertainty: Half (A) to one
third (T) of the OS treatment effect variance is explained by the
PFS treatment effect variance. Using limited data, sensitivity and
subgroup analysis did not explain result heterogeneity.
CANCER—Patient Reported Outcomes
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OBJECTIVES: To evaluate if quality-adjusted survival for tem-
sirolimus (TEMSR) met criteria for minimal clinically important
difference (MCID) in a randomized, outpatient study of ﬁrst-line
treatment of patients with poor-prognosis, advanced renal cell
carcinoma (RCC). In this study TEMSR (25 mg IV once-weekly)
was associated with median 10.9 months overall survival
(OS) compared with median 7.3 months OS for interferon
(IFN) (up to 18 MU subcutaneously thrice weekly (p = 0.008).
METHODS: OS was partitioned into 3 distinct periods: a) time
in serious toxicity (aggregated time in grade 3 or 4 adverse events
(AEs); b) time in progression (based on tumor response assess-
ment); and c) time without symptoms of progression or toxicity
(TWiST). Based on patient-reported responses to the EuroQol
(EQ-5D) at representative time points during each period,
Q-TWiST was estimated as the measure of quality-adjusted sur-
vival. Treatment group differences in Q-TWiST were evaluated in
terms of restricted means, with patient follow-up truncated at the
median of 17.9 months. Variance and covariance were estimated
using bootstrap methods. Following published literature, the
clinical importance of the TEMSR-IFN difference in Q-TWIST
was the percentage obtained when this difference was divided by
mean OS for IFN (the control group). RESULTS: All 626 ran-
domized patients were included in computation of health state
durations. Response rates for the EQ-5D were 87% (260/300)
during progression, 40% (230/570) during toxicity, and 99%
(278/279) during TWiST. Patients in the TEMSR group had 1.3
months greater Q-TWiST than those in the IFN group
(TEMSR = 7.0 months vs. IFN = 5.7 months; p = 0.0015). The
MCID was 14.8% (1.3 months divided by 8.8 months [IFN
mean OS]), which is within the published range of 10–15% for
MCID in cancer trials. CONCLUSION: Patients with advanced
RCC receiving TEMSR met criteria for clinically important
improvement in quality-adjusted survival.
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OBJECTIVES: The MABEL study is an open label, uncontrolled,
multi-centre, study of cetuximab in combination with irinotecan
in patients with EGFR expressing mCRC and having progressed
on a recent irinotecan-based treatment regimen. A study objec-
tive was to assess quality of life (QoL). This abstract will report
on ﬁndings on 126 patients from 28 UK sites. METHODS: QoL
was assessed using the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) and the EQ-5D. The QLQ-C30 questionnaire com-
prises 30 items, organised into global health status, functionality,
symptomatology and single items. The EQ-5D questionnaire
consists of the EQ-5D descriptive system and the Visual Ana-
logue Scale (VAS). QoL changes were assessed on patients with a
baseline and at least one post-baseline assessment. RESULTS: At
the 6 week assessment, 88 [69.8%] patients completed at least
one QoL item, with 71 [56.3%] patients at 12 weeks, and 41
[32.5%] patients at the end of the study visit. Given the loss of
two thirds of data by the end of study, the following results will
assess data over a 12 week period. Between baseline and 12
weeks the EORTC QLQ-C30 global health score increased
slightly from 65.3–68.9. Symptomatic scales reported a similar
trend with the exception of diarrhoea and ﬁnancial difﬁculties
single items. The EQ-5D index and VAS also reported a trend for
a slight improvement between baseline (0.73 and 0.90 respec-
tively) and 12 weeks (0.77 and 0.93 respectively.) CONCLU-
SION: It is important to consider these results in context of
patient prognosis and treatment administered. The data suggests
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